

ASX Announcement 8 July 2021

NUTRITIONAL GROWTH SOLUTIONS APPOINTS THREE SENIOR LEADERS TO DRIVE NEXT STAGE OF INTERNATIONAL GROWTH

Nutritional Growth Solutions Ltd. ("the Company" or "NGS", ASX:NGS), a global nutrition company that creates scientifically formulated and clinically proven supplements to support growth development in children, is pleased to announce that following a period of strong growth it has appointed three new senior roles to drive the Healthy Height® brand into its next stage of growth – a President in North America, a Commercial Director for China, and a Global Strategic Advisor.

Pharmaceutical veteran, Mr Stephen Turner, has been appointed as President in North America, bringing over 20 years' industry experience to the role. Mr Turner has worked for numerous multinational companies over his 24-year career including President and CEO for SCOLR Pharma, VP of Sales at PharmaCare and VP of Sales and Marketing at Strides Pharma.

Mr Turner will lead Nutritional Growth Solutions' operations in the United States, working closely with the Board and CEO to grow the Company and Healthy Height® brand into a household name for child nutrition. Mr Turner will lead the company's expansion into US retail exposure and wholesale distribution.

Ms Vicky Hou has been appointed as Commercial Director, China, and will drive the Company's sales and marketing efforts in the Chinese market. Ms Hou will be based in Sydney, Australia, and comes to NGS with 22 years' cross border experience including almost four years as Cross Border Sales Manager with multinational pharmaceutical and life sciences company, Bayer.

Finally, Ms Linda Luo has been appointed as Global Strategic Advisor and will implement the Company's global strategic direction, based in Melbourne, Australia. Ms Lou has worked in consumer goods, specifically in nutrition and child nutrition for 22 years for leading brands such as The A2 Milk Company, Blackmores and Bellamy's.

Commenting on the appointments, CEO of Nutritional Growth Solutions, Liron Fendell, said:

"Paediatric supplements are the nexus of infant formula, foods for special medical purposes, and nutritional supplements, which collectively is a market now worth more than US\$140 billion annually¹. With these expert appointments Nutritional Growth Solutions is now better positioned to increase its market share across current and new markets and deliver on our vision of being a leading household name for child nutrition, and the market leader globally for nutritional products to assist children reach their optimal height."

Nutritional Growth Solutions Ltd. ARBN 642 861 774

Israel: 4 Berkovich Street, Tel Aviv 6423806

Australia (Registered Local Agent): C/- Level 5, 126 Phillip Street, Sydney NSW 2000

www.ngsolutions.co

ASX Code: NGS

¹ Frost & Sullivan, July 2020



"The need for our products is universal, and we set ourselves apart from our competitors with products that are scientifically formulated by paediatric doctors, clinically proven to work and are filled with macro and micronutrients that are ideal for child growth."

"Each of our new senior hires comes to Nutritional Growth Solutions with a wealth of industry knowledge and will play a key role in driving our success into the future and more immediately, through our next stage of growth."

This announcement has been authorised for release by the Board of Directors of Nutritional Growth Solutions Ltd.

For more information:

Mr Brian Leedman Chairman, NG Solutions P: +61 (0) 412 281 780

E: bleedman@ngsolutions.co

Media

Tristan Everett Market Eye

P: +61 403 789 096

E: tristan.everett@marketeye.com.au

About Nutritional Growth Solutions

Nutritional Growth Solutions is a global nutritional health company focused on the well-being of children. NGS develops, produces and sells clinically tested nutritional supplement formulae for children following 20 years of medical research into pediatric nutrition at Schneider Children's Medical Centre, Israel's largest pediatric hospital. The nutritional supplements market has experienced tremendous growth in recent years, but most attention has been focused on adult users and children under three years of age. The three to twelve-year-old consumers represent a larger market opportunity and NGS is highly differentiated from its competitors with clinically tested products and an expanding product portfolio to capture this market opportunity.

ngsolutions.co